Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · see citing works

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · see citing works

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548 · see citing works

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,488 · see citing works

Improved survival in multiple myeloma and the impact of novel therapies

Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,238 · see citing works

A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA

Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161 · see citing works

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · see citing works

High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · see citing works

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · see citing works

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332 · see citing works

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · see citing works

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036 · see citing works

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · see citing works

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · see citing works

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920 · see citing works

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

Palumbo, A. P., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G. G., Miguel, J. F. S., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840 · see citing works

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817 · see citing works

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Cavo, M., Tacchetti, P., Patriarca, F. F., Petrucci, M. T., Pantani, L., Galli, M., Raimondo, F. D., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 815 · see citing works

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 800 · see citing works

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Miguel, J. F. S., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 793 · see citing works

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Jagannath, S., Barlogie, B., Berenson, J. R., Siegel, D. S. D., Irwin, D. H., Richardson, P. G. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 726 · see citing works

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721 · see citing works

Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 681 · see citing works

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Siegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 656 · see citing works

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hájek, R., Spencer, A. G., Miguel, J. F. S., Robak, T., Dmoszyńska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 644 · see citing works

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

Barlogie, B., Desikan, R. K., Eddlemon, P., Spencer, T., Zeldis, J. B., Munshi, N. C., Badros, A. Z., Zangari, M., Anaissie, E. J., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 539 · see citing works

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

Harousseau, J., Attal, M., Avet‐Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T. T. F., Casassus, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9158 · Cited by 529 · see citing works

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523 · see citing works

A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma

Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501 · see citing works

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

Maloney, D. G., Molina, A. J., Sahebi, F., Stockerl-Goldstein, K. E., Sandmaier, B. M., Bensinger, W., Storer, B. E., Hegenbart, U., Somlo, G., Chauncey, T. R., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2955 · Cited by 403 · see citing works

Allogeneic Bone Marrow Transplantation in Multiple Myeloma

Gahrton, G., Tura, S., Ljungman, P. T., Bélanger, C., Brandt, L., Cavo, M., Facon, T. T. F., Grañena, A., Gore, M. E., Gratwohl, A. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251802 · Cited by 377 · see citing works

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

Rajkumar, S. V., Rosiñol, L., Hussein, M. A., Catalano, J. V., Wiktor-Jędrzejczak, W., Lucy, L. M., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 341 · see citing works

Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

Schey, S., Fields, P. A., Bartlett, J. B., Clarke, I., Ashan, G., Knight, R., Streetly, M. J., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 312 · see citing works

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Cavo, M., Pantani, L., Petrucci, M. T., Patriarca, F. F., Zamagni, E., Donnarumma, D., Crippa, C., Boccadoro, M., Perrone, G., Falcone, A. P., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408898 · Cited by 307 · see citing works

Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Lonial, S., Vij, R., Harousseau, J., Facon, T. T. F., Moreau, P., Mazumder, A., Kaufman, J. L., Leleu, X. P., Tsao, L. C., Westland, C. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2649 · Cited by 295 · see citing works

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

Richardson, P. G. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., Mukhopadhyay, S., Ondovik, M. S., Khan, M. M. H., Paley, C. S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-481325 · Cited by 290 · see citing works

Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma

Ladetto, M., Pagliano, G., Ferrero, S., Cavallo, F., Drandi, D., Santo, L., Crippa, C., Rosa, L. D., Pregno, P., Grasso, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7172 · Cited by 264 · see citing works

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Vij, R., Wang, M. L., Kaufman, J. L., Lonial, S., Jakubowiak, A. J., Stewart, A. K., Kukreti, V., Jagannath, S., McDonagh, K. T., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-03-414359 · Cited by 254 · see citing works

A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

Glasmacher, A. G., Hahn, C., Hoffmann, F., Naumann, R., Goldschmidt, H., von Lilienfeld‐Toal, M., Orlopp, K. S., Schmidt‐Wolf, I. G. H., & Gorschlüter, M. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05914.x · Cited by 237 · see citing works

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Ocio, E. M., Richardson, P. G. G., Rajkumar, S. V., Palumbo, A. P., Mateos, M., Orlowski, R. Z., Kumar, S. K., Usmani, S. Z., Roodman, D., Niesvizky, R., et al. (2013) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 232 · see citing works

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

Dimopoulos, M. A., Siegel, D. S. D., Lonial, S., Qi, J., Hájek, R., Facon, T. T. F., Rosiñol, L., Williams, C. D., Blacklock, H. A., Goldschmidt, H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70398-x · Cited by 231 · see citing works

Plasma Cell Neoplasms

McKenna, R. W., & Linden, M. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-10918-3 · Cited by 194 · see citing works

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D. W., Masszi, T., Fontan, J., Michallet, M., Gratwohl, A. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4918 · Cited by 188 · see citing works

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

Reece, D. E., Song, K., Fu, T., Roland, B., Chang, H., Horsman, D. E., Mansoor, A., Chen, C. I., Masih‐Khan, E., Trieu, Y., et al. (2009) · Blood · doi:10.1182/blood-2008-12-193458 · Cited by 185 · see citing works

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning

Crawley, C. R., Iacobelli, S., Björkstrand, B., Apperley, J. F., Niederwieser, D. W., Gahrton, G., & for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2006) · Blood · doi:10.1182/blood-2006-07-036848 · Cited by 181 · see citing works

Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up

Björkstrand, B., Iacobelli, S., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Musto, P., Beksaç, M., Bosi, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7312 · Cited by 181 · see citing works

DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma

Lee, C., Barlogie, B., Munshi, N. C., Zangari, M., Fassas, A., Jacobson, J. L., van Rhee, F., Cottler‐Fox, M., Muwalla, F., & Tricot, G. J. K. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.055 · Cited by 175 · see citing works

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

Jagannath, S., Richardson, P. G. G., Barlogie, B., Berenson, J. R., Singhal, S., Irwin, D. H., Srkalović, G., Schenkein, D. P., Esseltine, D. L., & Anderson, K. C. (2006) · PubMed · Cited by 162 · see citing works

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Richardson, P. G. G., Siegel, D. S. D., Baz, R., Kelley, S. L., Munshi, N. C., Laubach, J. P., Sullivan, D. M., Alsina, M., Schlossman, R. L., Ghobrial, I. M., et al. (2012) · Blood · doi:10.1182/blood-2012-08-450742 · Cited by 162 · see citing works

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Richardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2679 · Cited by 162 · see citing works

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Richardson, P. G. G., Jagannath, S., Hussein, M. A., Berenson, J. R., Singhal, S., Irwin, D. H., WILLIAMS, S. F., Bensinger, W., Badros, A. Z., Vescio, R. A., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196238 · Cited by 158 · see citing works

New Drugs for Myeloma

Richardson, P. G. G., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., & Anderson, K. C. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-664 · Cited by 157 · see citing works

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

Dimopoulos, M. A., Hamilos, G., Zomas, A., Gika, D., Efstathiou, E., Grigoraki, V., Poziopoulos, C., Xilouri, I., Zorzou, M. P., Anagnostopoulos, N. I., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200326 · Cited by 144 · see citing works

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

Avet‐Loiseau, H., Soulier, J., Fermand, J., Yakoub‐Agha, I., Attal, M., Hulin, C., Garderet, L., Belhadj, K., Dorvaux, V., Minvielle, S., et al. (2010) · Leukemia · doi:10.1038/leu.2009.273 · Cited by 138 · see citing works

Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma

Kumar, S. K., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Geyer, S. M., Iturria, N. L., Fonseca, R., Hayman, S. R., Lust, J. A., Kyle, R. A., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.34 · Cited by 134 · see citing works

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age

Mileshkin, L. (2003) · Blood · doi:10.1182/blood-2002-09-2846 · Cited by 132 · see citing works

Adverse effects of thalidomide administration in patients with neoplastic diseases

Dimopoulos, M. A., & Eleutherakis-Papaiakovou, V. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.03.040 · Cited by 130 · see citing works

Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives

Dimopoulos, M. A., Anagnostopoulos, A., & Weber, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.200 · Cited by 129 · see citing works

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

Wang, M. L., Martin, T. G., Bensinger, W., Alsina, M., Siegel, D. S. D., Kavalerchik, E., Huang, M., Orlowski, R. Z., & Niesvizky, R. (2013) · Blood · doi:10.1182/blood-2013-07-511170 · Cited by 127 · see citing works

Treatment Options for Relapsed and Refractory Multiple Myeloma

Lonial, S., Mitsiades, C. S., & Richardson, P. G. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1805 · Cited by 126 · see citing works

Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity

Richardson, P. G. G., Schlossman, R. L., Jagannath, S., Alsina, M., Desikan, R. K., Blood, E., Weller, E. A., Mitsiades, C. S., Hideshima, T., Davies, F. E., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.875 · Cited by 126 · see citing works

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma

Palumbo, A., Gay, F., Bringhen, S., Falcone, A. P., Pescosta, N., Callea, V., Caravita, T., Morabito, F., Magarotto, V., Ruggeri, M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn018 · Cited by 124 · see citing works

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial

Richardson, P. G. G., Wolf, J., Jakubowiak, A. J., Zonder, J., Lonial, S., Irwin, D. H., Densmore, J. J., Krishnan, A. Y., Raje, N. S., Bar, M. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9788 · Cited by 121 · see citing works

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)

Knop, S. T., Gerecke, C., Liebisch, P., Topp, M. S., Platzbecker, U., Sezer, O., Vollmuth, C., Falk, K., Glasmacher, A., Maeder, U., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184135 · Cited by 120 · see citing works

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

Lentzsch, S., O'Sullivan, A., Kennedy, R. C., Abbas, M., Dai, L., Pregja, S. L., Burt, S., Boyiadzis, M. M., Roodman, G. D., Mapara, M. Y., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395715 · Cited by 119 · see citing works

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

Dimopoulos, M. A., Kastritis, E., Christoulas, D., Migkou, M., Gavriatopoulou, M., Gkotzamanidou, M. A., Iakovaki, M., Matsouka, C., Mparmparoussi, D., Ρούσσου, Μ., et al. (2010) · Leukemia · doi:10.1038/leu.2010.175 · Cited by 119 · see citing works

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

Jimenez-Zepeda, V. H., Mikhael, J. R., Winter, A., Franke, N., Masih‐Khan, E., Trudel, S., Chen, C. I., Kukreti, V., & Reece, D. E. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.044 · Cited by 117 · see citing works

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion

Sagaster, V., Ludwig, H., Kaufmann, H., Odelga, V., Zojer, N., Ackermann, J., Küenburg, E., Wieser, R., Zielinski, C. C., & Drach, J. W. (2006) · Leukemia · doi:10.1038/sj.leu.2404459 · Cited by 117 · see citing works

Low‐dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

Kyriakou, C. A., Thomson, K. J., D’Sa, S., Flory, A. J., Hanslip, J., Goldstone, A. H., & Yong, K. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05521.x · Cited by 115 · see citing works

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

Mikhael, J. R., Belch, A. R., Prince, H. M., Lucio, M. N., Maiolino, Â., Corso, A., Petrucci, M. T., Musto, P., Komarnicki, M. A., & Stewart, A. K. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07409.x · Cited by 108 · see citing works

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients

Morgan, G. J., Schey, S., Wu, P., Srikanth, M., Phekoo, K. J., Jenner, M. W., & Davies, F. E. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06538.x · Cited by 102 · see citing works

Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma

Reece, D. E., Rodriguez, G. P., Chen, C. I., Trudel, S., Kukreti, V., Mikhael, J. R., Pantoja, M. A., Xu, W., & Stewart, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2372 · Cited by 101 · see citing works

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Ludwig, H., Kasparu, H., Leitgeb, C., Rauch, E., Linkesch, W., Zojer, N., Greil, R., Seebacher, A., Pour, L., Weißmann, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-521468 · Cited by 100 · see citing works

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

Olin, R. L., Vogl, D. T., Porter, D., Luger, S. M., Schuster, S. J., Tsai, D. E., Siegel, D. L., Cook, R. J., Mangan, P. A., Cunningham, K., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.334 · Cited by 100 · see citing works

Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases

Rasche, L., Bernard, C., Topp, M. S., Kapp, M., Duell, J., Wesemeier, C., Haralambieva, E., Maeder, U., Einsele, H., & Knop, S. T. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1414-5 · Cited by 99 · see citing works

The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.

Knop, S. T., Straka, C., Haen, M., Schwedes, R., Hebart, H. F., & Einsele, H. (2005) · PubMed · Cited by 94 · see citing works

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

Niesvizky, R., Martin, T. G., Bensinger, W., Alsina, M., Siegel, D. S. D., Kunkel, L., Wong, A., Lee, S., Orlowski, R. Z., & Wang, M. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3352 · Cited by 81 · see citing works

Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability

Patriarca, F. F., Einsele, H., Spina, F., Bruno, B., Isola, M., Nozzoli, C., Nozza, A., Sperotto, A. A., Morabito, F., Stuhler, G., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.07.026 · Cited by 80 · see citing works

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

Lilienfeld‐Toal, M. V., Hahn‐Ast, C., Furkert, K., Hoffmann, F., Naumann, R., Bargou, R. C., Cook, G., & Glasmacher, A. G. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01121.x · Cited by 78 · see citing works

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

Jakubowiak, A. J., Siegel, D. S. D., Martin, T., Wang, M., Vij, R., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.152 · Cited by 77 · see citing works

Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.

Offidani, M., Corvatta, L., Marconi, M., Visani, G., Alesiani, F., Brunori, M., Galieni, P., Catarini, M., Burattini, M., Centurioni, R., et al. (2006) · PubMed · Cited by 77 · see citing works

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome

Brioli, A., Giles, H. V., Pawlyn, C., Campbell, J. P., Kaiser, M., Melchor, L., Jackson, G. H., Gregory, W. M., Owen, R. G., Child, J. A., et al. (2014) · Blood · doi:10.1182/blood-2013-12-542662 · Cited by 76 · see citing works

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Harrison, S. J., Quach, H., Link, E. K., Seymour, J. F., Ritchie, D. S., Ruell, S. A., Dean, J., Januszewicz, H., Johnstone, R. W., Neeson, P. J., et al. (2011) · Blood · doi:10.1182/blood-2011-03-339879 · Cited by 76 · see citing works

Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma

Qazilbash, M. H., Saliba, R. M., Lima, M. J. G. D., Hosing, C. M., Couriel, D. R., Aleman, A., Roden, L., Champlin, R. E., & Giralt, S. A. (2006) · Cancer · doi:10.1002/cncr.21700 · Cited by 76 · see citing works

The role of second autografts in the management of myeloma at first relapse.

Alvares, C. L., Davies, F. E., Horton, C., Patel, G. W., Powles, R., & Morgan, G. J. (2006) · PubMed · Cited by 72 · see citing works

Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma

Lemieux‐Blanchard, É., Hulin, C., Caillot, D., Tardy, S., Dorvaux, V., Michel, J., Gastinne, T., Rossi, C., Legouge, C., Touzeau, C., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.11.013 · Cited by 72 · see citing works

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Plesner, T., Lokhorst, H. M., Gimsing, P., Nahi, H., Lisby, S., & Richardson, P. G. G. (2012) · Blood · doi:10.1182/blood.v120.21.73.73 · Cited by 70 · see citing works

Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma

de Lavallade, H., Cheikh, J. E., Faucher, C., Fürst, S., Am, S., Coso, D., Bouabdallah, R., Chabannon, C., Gastaut, J. A., Blaise, D., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.22 · Cited by 68 · see citing works

Current strategies for treatment of relapsed/refractory multiple myeloma

Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A. J., Lonial, S., & Richardson, P. G. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 67 · see citing works

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study

Jakubowiak, A. J., Richardson, P. G. G., Zimmerman, T. M., Alsina, M., Kaufman, J. L., Kandarpa, M., Kraftson, S. J., Ross, C. W., Harvey, C., Hideshima, T., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09173.x · Cited by 62 · see citing works

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Heffner, L. T., Jagannath, S., Zimmerman, T. M., Lee, K. P., Rosenblatt, J. M., Lonial, S., Lutz, R. J., Czeloth, N., Osterroth, F., Ruehle, M., et al. (2012) · Blood · doi:10.1182/blood.v120.21.4042.4042 · Cited by 62 · see citing works

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Offidani, M., Corvatta, L., Maracci, L., Liberati, A. M., Ballanti, S., Attolico, I., Caraffa, P., Alesiani, F., di Toritto, T. C., Gentili, S., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.58 · Cited by 60 · see citing works

Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation

Kröger, N. M., Shimoni, A., Schilling, G., Schwerdtfeger, R., Bornhäuser, M., Nagler, A., Zander, A. R., Heinzelmann, M., Brand, R., Gahrton, G., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07984.x · Cited by 60 · see citing works

Autologous retransplantation for patients with recurrent multiple myeloma

Sellner, L., Heiß, C., Benner, A., Raab, M. S., Hillengaß, J., Hose, D., Lehners, N., Egerer, G., Ho, A. D., Goldschmidt, H., et al. (2013) · Cancer · doi:10.1002/cncr.28104 · Cited by 59 · see citing works

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study

Schey, S., Morgan, G. J., Ramasamy, K., Hazel, B., Ładoń, D., Corderoy, S., Jenner, M. W., Phekoo, K. J., Boyd, K. D., & Davies, F. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08250.x · Cited by 56 · see citing works

Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution

Tovar, N., de Larrea, C. F., Aróstegui, J. I., Cibeira, M. T., Rosiñol, L., Rovira, M., Elena, M. S., Filella, X., Yagüe, J., & Bladé, J. (2013) · Haematologica · doi:10.3324/haematol.2013.084350 · Cited by 55 · see citing works

D(T) PACE as salvage therapy for aggressive or refractory multiple myeloma

Gerrie, A. S., Mikhael, J. R., Cheng, L., Jiang, H., Kukreti, V., Panzarella, T., Reece, D. E., Stewart, K., Trieu, Y., Trudel, S., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12325 · Cited by 53 · see citing works

An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple Myeloma

Conner, T., Doan, Q. D., Walters, I. B., LeBlanc, A. L., & Beveridge, R. A. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.016 · Cited by 50 · see citing works

Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma

Weber, D. M., Graef, T. T., Hussein, M. A., Sobecks, R. M., Schiller, G. J., Lupinacci, L. C., Hardwick, J. S., & Jagannath, S. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.07.007 · Cited by 47 · see citing works

First thalidomide clinical trial in multiple myeloma: a decade

van Rhee, F., Dhodapkar, M. V., Shaughnessy, J. D., Anaissie, E. J., Siegel, D. S. D., Hoering, A., Zeldis, J. B., Jenkins, B., Singhal, S., Mehta, J., et al. (2008) · Blood · doi:10.1182/blood-2008-02-140954 · Cited by 44 · see citing works

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

Party, T. K. M. M. W., Kim, Y., Sohn, S., Lee, J.-H., Yang, D.-H., Moon, J., Ahn, J.-S., Kim, H., & Lee, J. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0856-x · Cited by 44 · see citing works

Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland

Hrusovsky, I., Emmerich, B., von Rohr, A., Voegeli, J., Taverna, C., Olie, R. A., Pliskat, H., Frohn, C., & Hess, G. (2010) · Oncology · doi:10.1159/000322866 · Cited by 44 · see citing works

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

Damaj, G. L., Malard, F., Hulin, C., Caillot, D., Garidi, R., Royer, B., Marit, G., Stoppa, A., Baños, A., Morineau, N., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.622422 · Cited by 44 · see citing works

Allogenic hematopoietic stem‐cell transplantation with reduced‐intensity conditioning in patients with refractory and recurrent multiple myeloma

Shimoni, A., Hardan, I., Ayuk, F. A., Schilling, G., Atanackovic, D., Zeller, W., Yerushalmi, R., Zander, A. R., Kröger, N. M., & Nagler, A. (2010) · Cancer · doi:10.1002/cncr.25228 · Cited by 42 · see citing works

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

Palumbo, A. P., Larocca, A., Falco, P., Sanpaolo, G., Falcone, A. P., Federico, V., Canepa, L., Crugnola, M., Genuardi, M., Magarotto, V., et al. (2010) · Leukemia · doi:10.1038/leu.2010.58 · Cited by 42 · see citing works

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

Dimopoulos, M. A., Beksaç, M., Benboubker, L., Roddie, H., Allietta, N., Broer, E., Couturier, C., Mazier, M., Angermund, R., & Facon, T. T. F. (2013) · Haematologica · doi:10.3324/haematol.2013.084376 · Cited by 39 · see citing works

The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma

Grover, J. K., Uppal, G., & Raina, V. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf258 · Cited by 38 · see citing works

Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma

Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Orlowski, R. Z., et al. (2013) · Blood · doi:10.1182/blood.v122.21.690.690 · Cited by 38 · see citing works

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma

Efebera, Y. A., Qureshi, S., Cole, S., Saliba, R. M., Pelosini, M., Patel, R. M., Koca, E., Mendoza, F. L., Wang, M. L., Shah, J. J., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.02.015 · Cited by 37 · see citing works

New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

Cea, M., Cagnetta, A., Gobbi, M., Patrone, F., Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2013) · PubMed · Cited by 37 · see citing works

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

Venner, C. P., Connors, J. M., Sutherland, H. J., Shepherd, J. D., Hamata, L., Mourad, Y. A., Barnett, M. J., Broady, R. C., Forrest, D. L., Hogge, D. E., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.531409 · Cited by 35 · see citing works

New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors

Cea, M., Cagnetta, A., Gobbi, M., Patrone, F., Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804581945 · Cited by 34 · see citing works

Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse

Papanikolaou, X. D., Repousis, P., Τζένου, Τ., Maltezas, D., Kotsopoulou, M., Megalakaki, K., Angelopoulou, M. K., Dimitrakoloulou, E., Koulieris, E., Bartzis, V., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.746683 · Cited by 33 · see citing works

Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma

Offidani, M., Corvatta, L., Marconi, M., Olivieri, A., Catarini, M., Mele, A., Brunori, M., Candela, M., Malerba, L., Capelli, D., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200401 · Cited by 32 · see citing works

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

Pönisch, W., Heyn, S., Beck, J., Wagner, I., Mohren, M., Hoffmann, F. A., Lange, T., Schmalfeld, M., Zehrfeld, T., Schwarzer, A., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12361 · Cited by 31 · see citing works

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

Richardson, P. G. G., Jagannath, S., Jakubowiak, A. J., Lonial, S., Raje, N. S., Alsina, M., Ghobrial, I. M., Schlossman, R. L., Mazumder, A., Munshi, N. C., et al. (2010) · Blood · doi:10.1182/blood.v116.21.3049.3049 · Cited by 30 · see citing works

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone‐refractory myeloma

van de Donk, N. W. C. J., Wittebol, S., Minnema, M. C., & Lokhorst, H. M. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07931.x · Cited by 27 · see citing works

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

Raje, N. S., Hari, P., Vogl, D. T., Jagannath, S., Orlowski, R. Z., Supko, J. G., Stephenson, P. A., Jones, S. S., Wheeler, C., & Lonial, S. (2012) · Blood · doi:10.1182/blood.v120.21.4061.4061 · Cited by 26 · see citing works

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

Shah, J. J., Zonder, J. A., Cohen, A. D., Bensinger, W., Kaufman, J. L., Orlowski, R. Z., Harvey, R. D., Abidi, M. H., Thomas, S. K., Walker, D., et al. (2012) · Blood · doi:10.1182/blood.v120.21.449.449 · Cited by 26 · see citing works

Discordant Response or Progression in Patients with Myeloma Treated with Thalidomide-based Regimens

ANAGNOSTOPOULOS, A., Hamilos, G., Zorzou, M. P., Grigoraki, V., Anagnostou, D., & Dimopoulos, M. A. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000151860 · Cited by 24 · see citing works

Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib

Smetana, J., Beránková, K., Zaoralová, R., Němec, P., Grešlíková, H., Kupská, R., Mikulášová, A., Fröhlich, J., Ševčı́ková, S., Zahradova, L., et al. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.11.012 · Cited by 23 · see citing works

Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14)

Leleu, X. P., Karlin, L., Macro, M., Hulin, C., Garderet, L., Roussel, M., Arnulf, B., Pegourié, B., Kolb, B., Stoppa, A., et al. (2013) · Blood · doi:10.1182/blood.v122.21.689.689 · Cited by 18 · see citing works

Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Ahn, J., Jung, S., Yang, D., Bae, S.-Y., Kim, Y., Kim, H., & Lee, J. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.02.004 · Cited by 16 · see citing works

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma

Chim, C. S., Lie, A. K. W., Chan, E. Y. T., Leung, Y.-H., Cheung, S., Chan, S. Y. T., Liang, R. H. S., & Kwong, Y. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0959-4 · Cited by 16 · see citing works

Daratumumab, a CD38 Monoclonal Antibody in Patients With Multiple Myeloma - Data From A Dose-Escalation Phase I/II Study

Plesner, T., Lokhorst, H. M., Gimsing, P., Nahi, H., Basse, L., Lisby, S., & Richardson, P. G. G. (2013) · University of Southern Denmark Research Portal (University of Southern Denmark) · Cited by 15 · see citing works

VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients

Buda, G., Orciuolo, E., Galimberti, S., Ghio, F., & Petrini, M. (2013) · Blood · doi:10.1182/blood.v122.21.5377.5377 · Cited by 14 · see citing works

Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

Raje, N. S., Faber, E. A., Richardson, P. G. G., Schiller, G. J., Hohl, R. J., Cohen, A. D., Forero, A., Carpenter, S. P., Cronier, D. M., Kaiser, C. J., et al. (2012) · Blood · doi:10.1182/blood.v120.21.447.447 · Cited by 13 · see citing works

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Baz, R., Martin, T. G., Alsina, M., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A. K., Chari, A., Sullivan, D. M., Nardelli, L. A., et al. (2014) · Blood · doi:10.1182/blood.v124.21.303.303 · Cited by 12 · see citing works

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma

Richardson, P. G. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., Mukhopadhyay, S., Ondovik, M. S., Khan, M. M. H., Paley, C. S., et al. (2013) · Blood · doi:10.1182/blood.v122.21.1970.1970 · Cited by 10 · see citing works

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Kumar, S. K., LaPlant, B. R., Chng, W. J., Zonder, J. A., Callander, N. S., Roy, V., Furth, B., Erlichman, C., & Stewart, K. (2012) · Blood · doi:10.1182/blood.v120.21.76.76 · Cited by 9 · see citing works

Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial

Rodon, P., Hulin, C., Pegourié, B., Tiab, M., Anglaret, B., Benboubker, L., Jardel, H., Decaux, O., Kolb, B., Roussel, M., et al. (2012) · Blood · doi:10.1182/blood.v120.21.4044.4044 · Cited by 8 · see citing works

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

Shah, J. J., Orlowski, R. Z., Alexanian, R., Wang, M. L., Thomas, S. K., Qazilbash, M. H., Parmar, S., Shah, N. D., Bashir, Q., Popat, U., et al. (2010) · Blood · doi:10.1182/blood.v116.21.1948.1948 · Cited by 6 · see citing works

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Nijhof, I. S., Zweegman, S., Levin, M., Koene, H. R., Beeker, A., Bloem, A. C., Bos, G. M. J., Faber, L. M., Klein, S. K., de Kruijf, E.-J. F. M., et al. (2013) · Blood · doi:10.1182/blood.v122.21.287.287 · Cited by 2 · see citing works

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Moreau, P., Miguel, J. F. S., Sonneveld, P., Mateos, M., Zamagni, E., Avet‐Loiseau, H., Hájek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 882 · see citing works

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Brudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 778 · see citing works

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Kumar, S. K., Harrison, S. J., Cavo, M., de la Rubia, J., Popat, R., Gasparetto, C., Hungria, V., Salwender, H. J., Suzuki, K., Kim, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30525-8 · Cited by 404 · see citing works

Multiple myeloma current treatment algorithms

Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 362 · see citing works

Epidemiology, Staging, and Management of Multiple Myeloma

Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332 · see citing works

The multiple myelomas — current concepts in cytogenetic classification and therapy

Kumar, S. K., & Rajkumar, S. V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0018-y · Cited by 302 · see citing works

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Moreau, P., Kumar, S. K., Miguel, J. F. S., Davies, F. E., Zamagni, E., Bahlis, N. J., Ludwig, H., Mikhael, J. R., Terpos, E., Schjesvold, F. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30756-7 · Cited by 280 · see citing works

CAR T cell therapies for patients with multiple myeloma

Mikkilineni, L., & Kochenderfer, J. N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0427-6 · Cited by 270 · see citing works

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

Shah, N. D., Li, L., McCarty, J. M., Kaur, I., Yvon, E. S., Shaim, H., Müftüoğlu, M., Liu, E., Orlowski, R. Z., Cooper, L. J. N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14570 · Cited by 218 · see citing works

Chimeric antigen receptor T-cell therapies for multiple myeloma

Mikkilineni, L., & Kochenderfer, J. N. (2017) · Blood · doi:10.1182/blood-2017-06-793869 · Cited by 213 · see citing works

Multiple myeloma in the marrow: pathogenesis and treatments

Fairfield, H. E., Falank, C. R., Avery, L. M., & Reagan, M. R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13038 · Cited by 188 · see citing works

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

Nijhof, I. S., van de Donk, N. W. C. J., Zweegman, S., & Lokhorst, H. M. (2017) · Drugs · doi:10.1007/s40265-017-0841-y · Cited by 144 · see citing works

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later

Robak, P. J., & Robak, T. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0269-9 · Cited by 141 · see citing works

CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity

Kararoudi, M. N., Nagai, Y., Elmas, E., Pereira, M. D. S. F., Ali, S. A., Imus, P. H., Wethington, D., Borrello, I., Lee, D. A., & Ghiaur, G. (2020) · Blood · doi:10.1182/blood.2020006200 · Cited by 131 · see citing works

Management of multiple myeloma in the relapsed/refractory patient

Sonneveld, P. (2017) · Hematology · doi:10.1182/asheducation-2017.1.508 · Cited by 108 · see citing works

Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma

Gherardin, N. A., Loh, L., Admojo, L., Davenport, A. J., Richardson, K., Rogers, A. J., Darcy, P. K., Jenkins, M. R., Prince, H. M., Harrison, S. J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22130-1 · Cited by 106 · see citing works

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Dimopoulos, M. A., Bringhen, S., Anttila, P., Capra, M., Cavo, M., Cole, C. E., Gasparetto, C., Hungria, V., Jenner, M. W., Vorobyev, V. I., et al. (2020) · Blood · doi:10.1182/blood.2020008209 · Cited by 84 · see citing works

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective

Rajkumar, S. V., & Harousseau, J. L. (2016) · Blood · doi:10.1182/blood-2016-09-692947 · Cited by 80 · see citing works

How I treat myeloma with new agents

Moreau, P. (2017) · Blood · doi:10.1182/blood-2017-05-743203 · Cited by 81 · see citing works

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

Goldschmidt, H., Ashcroft, J., Szabó, Z. R., & Garderet, L. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3546-8 · Cited by 80 · see citing works

Safety of proteasome inhibitors for treatment of multiple myeloma

Schlafer, D., Shah, K. S., Panjic, E. H., & Lonial, S. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1259310 · Cited by 71 · see citing works

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Touzeau, C., Krishnan, A. Y., Moreau, P., Perrot, A., Usmani, S. Z., Manier, S., Cavo, M., Chamorro, C. M., Nooka, A. K., Martin, T. G., et al. (2024) · Blood · doi:10.1182/blood.2023023616 · Cited by 71 · see citing works

Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design

Richardson, P. G. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A., Risse, M., Corzo, K. P., & Anderson, K. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 71 · see citing works

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

Orlowski, R. Z., Moreau, P., Niesvizky, R., Ludwig, H., Oriol, A., Chng, W. J., Goldschmidt, H., Yang, Z., Kimball, A. S., & Dimopoulos, M. A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.04.018 · Cited by 70 · see citing works

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma

Lernia, G. D., Leone, P., Solimando, A. G., Buonavoglia, A., Saltarella, I., Ria, R., Ditonno, P., Silvestris, N., Crudele, L., Vacca, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020552 · Cited by 70 · see citing works

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

Laubach, J. P., Schjesvold, F. H., Mariz, M., Dimopoulos, M. A., Lech‐Marańda, E., Špıčka, I., Hungria, V., Shelekhova, T. V., Abdo, A., Jacobasch, L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30680-x · Cited by 69 · see citing works

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

Moreau, P., Zamagni, E., & Mateos, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68 · see citing works

How I treat first relapse of myeloma

Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 66 · see citing works

A clinical perspective on plasma cell leukemia; current status and future directions

Tuazon, S. A., Holmberg, L., Nadeem, O., & Richardson, P. G. G. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00414-6 · Cited by 66 · see citing works

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Ailawadhi, S., Kelly, K. R., Vescio, R. A., Jagannath, S., Wolf, J. L., Gharibo, M. M., Sher, T., Bojanini, L., Kirby, M. W., & Chanan-Khan, A. A. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.018 · Cited by 65 · see citing works

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma

Xu, J., Wang, Q., Xu, H., Gu, C., Jiang, L., Wang, J., Wang, D., Xu, B., Mao, X., Wang, J., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0672-7 · Cited by 62 · see citing works

Ixazomib for the treatment of multiple myeloma

Richardson, P. G. G., Zweegman, S., O’Donnell, E., Laubach, J. P., Raje, N. S., Voorhees, P. M., Ferrari, R. H., Skácel, T., Kumar, S. K., & Lonial, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528229 · Cited by 61 · see citing works

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients

Botta, C., Ciliberto, D., Rossi, M., Staropoli, N., Cucè, M., Galeano, T., Tagliaferri, P., & Tassone, P. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003905 · Cited by 60 · see citing works

Treatment of relapsed multiple myeloma: Evidence-based recommendations

Durer, C., Durer, S., Lee, S., Chakraborty, R., Malik, M. N., Rafae, A., Zar, M. A., Kamal, A., Rosko, N., Samaras, C. J., et al. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100616 · Cited by 55 · see citing works

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

Mikhael, J., Richter, J., Vij, R., Cole, C., Zonder, J., Kaufman, J. L., Bensinger, W., Dimopoulos, M., Lendvai, N., Hari, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0857-2 · Cited by 54 · see citing works

Treatment of relapsed and refractory multiple myeloma

Lee, J. H., & Kim, S. (2020) · Blood Research · doi:10.5045/br.2020.s008 · Cited by 50 · see citing works

BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma

Yang, J., Zhou, W., Li, D., Niu, T., & Wang, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215949 · Cited by 49 · see citing works

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Dimopoulos, M.-A., Richardson, P., & Lonial, S. (2022) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2022.01.011 · Cited by 46 · see citing works

Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions

Moreau, P., & de Wit, E. (2017) · British Journal of Haematology · doi:10.1111/bjh.14780 · Cited by 45 · see citing works

Multiple Myeloma Guidelines and Their Recent Updates: Implications for Imaging

Mosebach, J., Thierjung, H., Schlemmer, H.-P., & Delorme, S. (2019) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-0897-3966 · Cited by 44 · see citing works

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

Ríos, R., Agustin, M.-G., Alarcón-Payer, C., Dolores, S.-R., María, V. D. D. L. G. A., Collado, C. G., Alberto, J. M., Manuel, J. C., & Barrera, J. C. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s115456 · Cited by 42 · see citing works

Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma

Huynh, M., Pak, C., Markovina, S. S., Callander, N. S., Chng, K. S., Wuerzberger‐Davis, S. M., Bakshi, D. D., Kink, J. A., Hematti, P., Hope, C. L., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000667 · Cited by 41 · see citing works

Identification of PIKfyve kinase as a target in multiple myeloma

de Campos, C. B., Zhu, Y. X., SEPETOV, N. F., Romanov, S., Bruins, L. A., Shi, C.-X., Stein, C. K., Petit, J. L., Polito, A. N., Sharik, M. E., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.222729 · Cited by 41 · see citing works

SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation

Yu, X. M., Fang, B., Liu, Y., Yan, S., Cao, D., Mei, H., Wang, Q., Hu, Y., & Guo, T. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117971 · Cited by 40 · see citing works

How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review

LeBlanc, M. R., Hirschey, R., Bryant, A. L., LeBlanc, T. W., & Smith, S. K. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02392-6 · Cited by 38 · see citing works

Cold atmospheric plasma as a potential tool for multiple myeloma treatment

Xu, D., Xu, Y., Cui, Q., Liu, D., Liu, Z., Wang, X., Yang, Y., Feng, M., Liang, R., Chen, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24649 · Cited by 38 · see citing works

Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma

Laubach, J. P., Prada, C. P., Richardson, P. G. G., & Longo, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.550 · Cited by 35 · see citing works

New proteasome inhibitors in the treatment of multiple myeloma

Hungria, V. T. D. M., Crusoé, E. D. Q., Bittencourt, R., Maiolino, Â., Magalhães, R., Sobrinho, J., Pinto, J. V., Fortes, R., Moreira, E. D. S., & Tanaka, P. (2018) · Hematology, Transfusion and Cell Therapy · doi:10.1016/j.htct.2018.07.003 · Cited by 33 · see citing works

Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Shi, C.-X., Zhu, Y. X., Bruins, L. A., de Campos, C. B., Stewart, W., Braggio, E., & Stewart, A. K. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1026 · Cited by 36 · see citing works

Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design

Nooka, A. K., Weisel, K. C., van de Donk, N. W. C. J., Routledge, D. J. M., Rodríguez‐Otero, P., Song, K., Quach, H., Callander, N. S., Minnema, M. C., Trudel, S., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1269 · Cited by 37 · see citing works

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors

Gengenbach, L., Graziani, G., Reinhardt, H., Rösner, A., Braun, M., Möller, M., Greil, C., Wäsch, R., & Engelhardt, M. M. (2021) · Cancers · doi:10.3390/cancers13174320 · Cited by 35 · see citing works

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab

Shen, F., & Shen, W. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221106563 · Cited by 35 · see citing works

Hematogenous extramedullary relapse in multiple myeloma ‐ a multicenter retrospective study in 127 patients

Avivi, I. M., Cohen, Y. C., Suska, A., Shragai, T., Mikala, G., Garderet, L., Gueye, M. S., Glickman, S., Jayabalan, D. S., Niesvizky, R., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25579 · Cited by 34 · see citing works

Doxorubicin-Loaded PEG-CdTe Quantum Dots as a Smart Drug Delivery System for Extramedullary Multiple Myeloma Treatment

Chen, D., Chen, B., & Yao, F. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2782-0 · Cited by 32 · see citing works

A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma

Cook, G., Zweegman, S., Mateos, M., Suzan, F., & Moreau, P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.016 · Cited by 31 · see citing works

Current approaches to management of high‐risk multiple myeloma

Goldman‐Mazur, S., & Kumar, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26161 · Cited by 32 · see citing works

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis

Bringhen, S., Pour, L., Vorobyev, V. I., Vural, F., Warzocha, K., Benboubker, L., Koh, Y., Maisnar, V., Karlin, L., Pavic, M., et al. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106576 · Cited by 31 · see citing works

Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation

Lisenko, K., Pavel, P., Kriegsmann, M., Bruckner, T. M., Hillengaß, J., Goldschmidt, H., Witzens‐Harig, M., Ho, A. D., & Wuchter, P. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.12.631 · Cited by 31 · see citing works

Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma

Leoh, L. S., Kim, Y. K., Candelaria, P. V., Martı́nez-Maza, O., Daniels‐Wells, T. R., & Penichet, M. L. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700787 · Cited by 31 · see citing works

Outcomes after biochemical or clinical progression in patients with multiple myeloma

Goldman‐Mazur, S., Visram, A., Kapoor, P., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., Kourelis, T., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007082 · Cited by 30 · see citing works

Drug targets and resistance mechanisms in multiple myeloma

Naß, J., & Efferth, T. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.04 · Cited by 28 · see citing works

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma

Ahmedzai, S. H., Snowden, J. A., Ashcroft, A. J., Cairns, D. A., Williams, C. D., Hockaday, A., Cavenagh, J. D., Ademokun, D., Tholouli, E., Allotey, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01006 · Cited by 27 · see citing works

MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells

Huang, F.-I., Wu, Y.-W., Sung, T.-Y., Liou, J., Lin, M., Pan, S., & Yang, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00249 · Cited by 27 · see citing works

Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation

Möller, M., Ihorst, G., Pahl, A., Scheubeck, S., Barsch, F., Dold, S. M., Bertz, H., Arends, J., Wäsch, R., & Engelhardt, M. M. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.11.003 · Cited by 28 · see citing works

LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β‐catenin/cyclin D1 signaling via PLAGL2

Liu, Q., Ran, R., Song, M., Li, X., Wu, Z., Guanrong, D., & Xia, R. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09628-7 · Cited by 27 · see citing works

Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial

Xia, J., Sun, Q., Zhou, D., Li, H., Wang, Y., Qi, Y., Cao, J., Yan, Z., Li, D., Cheng, H., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00048-1 · Cited by 27 · see citing works

Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review

Sparano, F., Cavo, M., Niscola, P., Caravita, T., & Efficace, F. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4137-x · Cited by 26 · see citing works

Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma

Shi, J., Song, S., Han, H., Xu, H., Huang, M., Qian, C., Zhang, X., Ouyang, L., Hong, Y., Zhuang, W., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00554 · Cited by 26 · see citing works

Myelosuppression, Bone Disease, and Acute Renal Failure: Evidence-Based Recommendations for Oncologic Emergencies

Brigle, K. E., Pierre, A. E., Finley-Oliver, E., Faiman, B. M., Tariman, J. D., Miceli, T. S., & and Board (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.s5.60-76 · Cited by 26 · see citing works

Applying stem cell therapy in intractable diseases: a narrative review of decades of progress and challenges

Brianna, B., Ling, A. P. K., & Wong, Y. P. (2022) · Stem Cell Investigation · doi:10.21037/sci-2022-021 · Cited by 24 · see citing works

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

Garderet, L., Iacobelli, S., Köster, L., Goldschmidt, H., Johansson, J., Bourhis, J. H., Krejčí, M., Leleu, X. P., Potter, M. N., Blaise, D., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.035 · Cited by 25 · see citing works

Progression with clinical features is associated with worse subsequent survival in multiple myeloma

Chakraborty, R., Liu, H. D., Rybicki, L. A., Tomer, J., Khouri, J., Dean, R. M., Faiman, B. M., Kalaycio, M. E., Samaras, C. J., Majhail, N. S., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25415 · Cited by 24 · see citing works

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis

Moreau, P., Dimopoulos, M. A., Richardson, P. G. G., Siegel, D. S. D., Cavo, M., Corradini, P., Weisel, K. C., Delforge, M., O’Gorman, P., Song, K., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12903 · Cited by 24 · see citing works

Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop

Tan, D. C. L., Lee, J. H., Chen, W.-M., Shimizu, K., Hou, J., Suzuki, K., Nawarawong, W., Huang, S., Chim, C. S., Kım, K., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1427858 · Cited by 25 · see citing works

Therapeutic progress in relapsed/refractory multiple myeloma

Chen, Q., Zhang, M., Zheng, S., Tong, Y., & Tan, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05730-y · Cited by 23 · see citing works

Primary Plasma Cell Leukemia: Identity Card 2016

Musto, P., Simeon, V., Todoerti, K., & Neri, A. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0392-6 · Cited by 22 · see citing works

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan

Nieto, Y. L., Valdez, B. C., Pingali, S. R., Bassett, R. L., Delgado, R., Nguyen, J., Shah, N. D., Popat, U., Jones, R. B., Andersson, B. S., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30080-7 · Cited by 22 · see citing works

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

Kastritis, E., Ρούσσου, Μ., Gavriatopoulou, M., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., Ziogas, D. C., Fotiou, D., Ntanasis‐Stathopoulos, I., Dialoupi, I., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000539 · Cited by 22 · see citing works

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma

Usmani, S. Z., Karanes, C., Bensinger, W., D’Souza, A., Raje, N. S., Tuchman, S. A., Sborov, D. W., Laubach, J. P., Bianchi, G., Kanagavel, D., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01262-w · Cited by 22 · see citing works

Safety of ixazomib for the treatment of multiple myeloma

Bonnet, A., & Moreau, P. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1344212 · Cited by 21 · see citing works

Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation

Patriarca, F. F., Bruno, B., Einsele, H., Spina, F., Giaccone, L., Montefusco, V., Isola, M., Nozzoli, C., Nozza, A., Morabito, F., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.10.014 · Cited by 21 · see citing works

New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib

Richardson, P. G. G., Kumar, S. K., Laubach, J. P., Paba‐Prada, C. E., Gupta, N., Berg, D. T., de Velde, H. J. V., & Moreau, P. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s102328 · Cited by 20 · see citing works

Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study

Richardson, P. G. G., Harrison, S. J., Bringhen, S., Schjesvold, F. H., Yong, K., Campana, F., Le-Guennec, S., Macé, S., & Dimopoulos, M. A. (2021) · Future Oncology · doi:10.2217/fon-2021-0568 · Cited by 20 · see citing works

Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Haertle, L., Barrio, S., Munawar, U., Han, S., Zhou, X., Šimíček, M., Vogt, C., Truger, M. S., Alonso, R., Steinhardt, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1161 · Cited by 20 · see citing works

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

Katodritou, E., Kyrtsonis, M., Delimpasi, S., Kyriakou, D. S., Symeonidis, A. S., Spanoudakis, E., Vasilopoulos, G., Anagnostopoulos, Α., Kioumi, A., Zikos, P., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3361-2 · Cited by 20 · see citing works

Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells

Wang, B., Lyu, H., Pei, S., Song, D., Ni, J., & Liu, B. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1464849 · Cited by 18 · see citing works

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

Dimopoulos, M. A., Niesvizky, R., Weisel, K. C., Siegel, D. S. D., Hájek, R., Mateos, M., Cavo, M., Huang, M., Zahlten‐Kumeli, A., & Moreau, P. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0300-y · Cited by 19 · see citing works

Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse

Smetana, J., Oppelt, J., Štork, M., Pour, L., & Kuglík, P. (2018) · Molecular Cytogenetics · doi:10.1186/s13039-018-0357-5 · Cited by 18 · see citing works

Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients

Jamet, B., Bailly, C., Carlier, T., Planche, L., Touzeau, C., Kraeber‐Bodéré, F., Moreau, P., & Bodet‐Milin, C. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1459602 · Cited by 16 · see citing works

Methodological aspects of health‐related quality of life measurement and analysis in patients with multiple myeloma

Nielsen, L. K., Abildgaard, N., Jarden, M., & Klausen, T. (2019) · British Journal of Haematology · doi:10.1111/bjh.15759 · Cited by 16 · see citing works

Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group

Bila, J., Katodritou, E., Guenova, M. L., Bašić‐Kinda, S., Coriu, D., Dapcevic, M., Ibricevic-Balić, L., Ivanaj, A., Каранфилски, О., Zver, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173940 · Cited by 16 · see citing works

Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting

Wang, J., Gu, T., Hu, Y., & Huang, H. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00316-8 · Cited by 16 · see citing works

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma

Mark, T. M., Forsberg, P. A., Rossi, A., Pearse, R. N., Pekle, K. A., Perry, A., Boyer, A. S., Tegnestam, L., Jayabalan, D. S., Coleman, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028027 · Cited by 16 · see citing works

DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

Khouri, J., Faiman, B. M., Grabowski, D., Mahfouz, R. Z., Khan, S. N., Wei, W., Valent, J. N., Dean, R. M., Samaras, C. J., Jha, B. K., et al. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.12.004 · Cited by 16 · see citing works

Effects of time delays in a mathematical bone model

Wang, L., Qiu, K., & Jia, Y. (2017) · Chinese Physics B · doi:10.1088/1674-1056/26/3/030503 · Cited by 15 · see citing works

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma

Kinahan, C., Mangone, M. A., Scotto, L., Visentin, M., Marchi, E., Cho, H. J., & O’Connor, O. A. (2020) · Oncotarget · doi:10.18632/oncotarget.27516 · Cited by 15 · see citing works

Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum

Kansai Myeloma Forum Investigators, Matsumura‐Kimoto, Y., Kuroda, J., Kaneko, H., Kamitsuji, Y., Fuchida, S., Nakaya, A., Shibayama, H., Uoshima, N., Yokota, I., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2416-4 · Cited by 15 · see citing works

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Nawrocki, S. T., Olea, J., Celi, C. V., Dadrastoussi, H., Wu, K., Tsao-Wei, D. D., Colombo, A., Coffey, M. C., Hernandez, E. F., Chen, X., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0229 · Cited by 14 · see citing works

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Parisi, M. S., Leotta, S., Romano, A., Fabro, V. D., Martino, E. A., Calafiore, V., Giubbolini, R., Markovic, U., Leotta, V., Giorgio, M. A. D., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101695 · Cited by 14 · see citing works

The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma

Gu, J., Song, S., Han, H., Xu, H., Gao, F., Qian, C., Qiu, Y., Zhou, W., Zhuang, W., & Li, B.-Z. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00880 · Cited by 14 · see citing works

Treatment strategies for relapsed and refractory multiple myeloma

Zhang, H. (2017) · 中国综合临床 · doi:10.3760/cma.j.issn.1008-6315.2017.02.102

Management of relapsed multiple myeloma

Musteaţă, V. G., & Мустяцэ, В. Г. (2021)

How I treat relapsed myeloma

Bladé, J., Rosiñol, L., & de Larrea, C. F. (2015) · Blood · doi:10.1182/blood-2014-10-551531 · Cited by 30 · see citing works

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Moreau, P., Kumar, S. K., Miguel, J. F. S., Davies, F. E., Zamagni, E., Bahlis, N. J., Ludwig, H., Mikhael, J. R., Terpos, E., Schjesvold, F. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30756-7 · Cited by 280 · see citing works

Practical Considerations in Managing Relapsed Multiple Myeloma

Agarwal, A., Chow, E., Bhutani, M., Voorhees, P. M., Friend, R. N., & Usmani, S. Z. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.11.010 · Cited by 14 · see citing works